Drug arrives years after pandemic’s peak, but could still offer protection to vulnerable populations.
An antiviral pill has, for the first time, been shown to prevent COVID-19 in people exposed to the SARS-CoV-2 virus at home, according to trial results published today in the New England Journal of Medicine1. The drug could be a lifeline for those who still face real danger from the virus, such as care-home residents or transplant recipients on immune-suppressing medication.
There are good things happening in the world.
You can read about it here without a paywall.
Households exposed to COVID-19 now have an oral drug specifically cleared to prevent infection after contact with a sick person. The FDA listed Xocova, the brand name for ensitrelvir, as a 2026 novel drug approval for post-exposure prophylaxis of COVID-19 following contact with an infected individual. The decision fills a gap that has persisted since the pandemic’s early years: until now, no oral antiviral carried an FDA-approved indication for prevention rather than treatment.



















